Rhinosinusitis: Establishing definitions for clinical research and patient care.
Journal Information
Journal Title: Otolaryngol Head Neck Surg
Detailed journal information not available.
Publication Details
Subject Category: Otorhinolaryngology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure of potential conflict of interest: E. O. Meltzer has consulting arrangements with Alcon, Altana, AstraZeneca, Aventis, Dey, Genentech, GlaxoSmithKline, Merck, Medpointe, Novartis, Pfizer, Schering-Plough, and Wyeth; receives grants-research support from Alcon, Altana, AstraZeneca, Aventis, Dey, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Schering-Plough; and is on the Speaker’s Bureau for Aventis, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Pfizer, and Schering-Plough, D. L. Hamilos—none disclosed. J. Hadley has consultant arrangements with Abbott, Aventis, Bayer, GlaxoSmithKline, Merck, GE Medical Systems, Pfizer, and Schering-Plough and is on the Speaker’s Bureau for Abbott, Aventis, Bayer, GlaxoSmithKline, Merck, Pfizer, and Schering-Plough. D. Lanza is on the Speaker’s Bureau for AstraZeneca. B. F. Marple has consulting arrangements with Alcon, Aventis, and Bayer and receives grants-research support from Aventis, GlaxoSmithKline, Abbott, Merck, and Bayer. R. Nicklas—none disclosed. C. Bachert—none disclosed. J. Baraniuk has consultant arrangements with Roche, Centecor, GlaxoSmithKline, Astra-Zeneca, and Aventis; has patent-licensing arrangements with Georgetown University; receives grants-research support from the National Institutes of Health; and is employed by Georgetown University. F. M. Baroody is on the Speaker’s Bureau for Merck & Co, Inc, and GlaxoSmithKline. M. S. Benninger has consultant arrangements with Aventis, GlaxoSmithKline, Ortho-McNeil, Abbott, and Bayer; receives grants-research support from Novartis and Bayer; is on the Speaker’s Bureau for Aventis and GlaxoSmithKline. I. Brook is on the Speaker’s Bureau for Abbott. B. A. Chowdhury—none disclosed. H. M. Druce is employed by Phys Inc. S. Durham has consultant arrangements with ALK Abello, UCB, and GlaxoSmithKline; receives grants-research support from ALK Abello and GlaxoSmithKline; and is on the Speaker’s Bureau for ALK Abello, UCB, Aventis, and WAO. B. Ferguson has consulting arrangements with Aventis, Abbott, and GlaxoSmithKline; is on the Speaker’s Bureau for Aventis, Astra Zeneca, Abbott, Merck, GlaxoSmithKline, and Pfizer; and is an advisor for Pfizer. J. M. Gwaltney, Jr—none disclosed. M. Kaliner has consultant arrangements with Aventis, Novartis, GlaxoSmithKline, Genentech, and Abbott; receives grants-research support from Astra Zeneca, Aventis, Boehringer-Ingelheim, GlaxoSmithKline, and Schering-Plough; is on the Speaker’s Bureau for Aventis, Abbott, GlaxoSmithKline, Medpointe, Novartis, and Genentech. D. Kennedy has consulting arrangements with Aventis, Novartis, Medtronic-Xomed, and Schering-Plough; received grants-research support from Novartis; and has patent-licensing arrangements with Medtronic-Xomed. V. Lund has consulting arrangements with Schering-Plough and Bayer. R. Naclerio has consulting arrangements with Merck and Schering-Plough; receives grants-research support from Corixa and Merck; and is on the Speaker’s Bureau for Merck and GlaxoSmithKline. R. Pawankar—none disclosed. J. F. Piccirillo—none disclosed. P. Rohane is employed by Celgene Corp. R. Simon—none disclosed. R. Slavin has consultant arrangements with Aventis; receives grants-research support from GlaxoSmithKline, Genentech, and AstraZeneca; and is on the Speaker’s Bureau of Aventis, Schering-Plough, Genentech, and AstraZeneca. A. Togias has consultant arrangement with AstraZeneca, Genentech, GlaxoSmithKline, Novartis, and Merck; receives grants-research support from Merck and Genentech; and is on the Speaker’s Bureau for Genentech, Merck, Novartis, Pfizer, and UCB. E. R. Wald receives grants-research support from Aventis, GlaxoSmithKline, Wyeth, Abbott, and Medimmune. J. Zinreich—none disclosed."
"The leadership of the participating organizations would like to especially thank Drs Meltzer and Hamilos for the amount of personal time and effort devoted to the development and completion of this project. The editors and participating organizations are also grateful to the AAAAI for organizing this conference and to the national and international experts who participated. We are also very appreciative of Schering’s unrestricted grant to fund the meeting and the publication of the conference’s proceedings. We would like to thank Jerome Schultz for his administrative contributions for the meeting and publications, and Maria Bavishi for assistance in developing this consensus document, as well as Dr Jens Ponikau for providing an additional review of this manuscript. The leadership of the participating organizations would like to especially thank Drs Meltzer and Hamilos for the amount of personal time and effort devoted to the development and completion of this project. The editors and participating organizations are also grateful to the AAAAI for organizing this conference and to the national and international experts who participated. We are also very appreciative of Schering’s unrestricted grant to fund the meeting and the publication of the conference’s proceedings. We would like to thank Jerome Schultz for his administrative contributions for the meeting and publications, and Maria Bavishi for assistance in developing this consensus document, as well as Dr Jens Ponikau for providing an additional review of this manuscript."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025